The U.S. Food and Drug Administration today approved Cytalux (pafolacianine), an imaging drug intended to assist surgeons in identifying ovarian cancer lesions. The drug is designed to improve the ability to locate additional ovarian cancerous tissue that is normally difficult to detect during surgery.
Cytalux is indicated for use in adult patients with ovarian cancer to help identify cancerous lesions during surgery. The drug is a diagnostic agent that is administered in the form of an intravenous injection prior to surgery.
- Read more about FDA Approves New Imaging Drug to Help Identify Ovarian Cancer Lesions
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/fda-approves-new-imaging-drug-to-help-identify-ovarian-cancer-lesions
No comments:
Post a Comment